{
    "nct_id": "NCT04977375",
    "official_title": "Phase Ib/II Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma",
    "inclusion_criteria": "* Age 18 years or older\n* Confirmed histologic diagnosis of WHO Grade IV, Glioblastoma Multiforme\n* GBM recurrence or progression with planned standard of care surgical resection and repeat radiation\n* Tumor size less than 6 cm\n* ECOG performance status of 0-1\n* Adequate laboratory values\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Contraindication to additional radiation\n* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor\n* Immunodeficiency diagnosis or receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone) or any other form of immunosuppressive therapy\n* Severe hypersensitivity to pembrolizumab\n\nComplete inclusion/exclusion criteria are detailed in the protocol.",
    "miscellaneous_criteria": ""
}